Characterization of humoral and cellular immunity to rubella vaccine in four distinct cohorts

Immunologic Research

Volumn 58, Issue 1, 2014, Pages 1-8

  Lambert, Nathaniel D ^a   Haralambieva, Iana H ^a   Ovsyannikova, Inna G ^a   Larrabee, Beth R ^a   Pankratz, V Shane ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibodies; Cytokines; Immunity; Immunity, cellular; Immunity, humoral; Measles mumps rubella vaccine; Polymorphism, single nucleotide; Receptors, cytokine

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; RUBELLA VACCINE;

ADOLESCENT; ADULT; ARTICLE; CELLULAR IMMUNITY; CHILD; COHORT ANALYSIS; CYTOKINE RELEASE; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RUBELLA; RUBELLA VIRUS; SCHOOL CHILD; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; CALIFORNIA; CHILD; COHORT STUDIES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MINNESOTA; RUBELLA; RUBELLA VACCINE; RUBELLA VIRUS; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84893810400     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8475-y     Document Type: Article

References (51)

1. Wise J. Small rise in rubella cases triggers warning. BMJ. 2013;346:f2935.
2. Paradowska-Stankiewicz I, Czarkowski MP, Derrough T, Stefanoff P. Ongoing outbreak of rubella among young male adults in Poland: increased risk of congenital rubella infections. Euro Surveill 2013;18(21).
3. Nationwide rubella epidemic in Japan, 2013. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/Health Section of the Secretariat of the League of Nations 2013 Jun 14;88(24):251-6.
4. Organization WH. Global measles and rubella strategic plan 2012-2020. Geneva; 2012.
5. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001;20(1):63-75.
6. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998;47(RR-8):1-57.
7. Prevention CfDCa. Epidemiology and prevention of vaccine-preventable diseases. 12th, second printing ed. Washington, DC: Public Health Foundation; 2012.
8. Remington JS, Klein JO, Wilson CB, Nizet V, Maldonado Y. Infectious diseases of the fetus and newborn. Philadelphia: Elsevier Saunders; 2010.
9. O'Shea S, Best JM, Banatvala JE. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis. 1983;148(4):639-47.
10. Honeyman MC, Forrest JM, Dorman DC. Cell-mediated immune response following natural rubella and rubella vaccination. Clin Exp Immunol. 1974;17(4):665-71.
11. Allmendinger J, Paradies F, Kamprad M, Richter T, Pustowoit B, Liebert UG. Determination of rubella virus-specific cell-mediated immunity using IFN gamma-ELISpot. J Med Virol. 2010;82(2):335-40.
12. Pukhalsky AL, Shmarina GV, Bliacher MS, Fedorova IM, Toptygina AP, Fisenko JJ, et al. Cytokine profile after rubella vaccine inoculation: evidence of the immunosuppressive effect of vaccination. Mediators Inflamm. 2003;12(4):203-7.
13. Dhiman N, Haralambieva IH, Vierkant RA, Pankratz VS, Ryan E, Jacobson RM, et al. Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in health vaccinees. Cytokine. 2010;50:24-9.
14. Haralambieva IH, Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, et al. 2′-5′-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine. Hum Immunol. 2010;71(4):383-91.
15. Ovsyannikova IG, Haralambieva IH, Dhiman N, O'Byrne MM, Pankratz VS, Jacobson RM, et al. Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis. 2010;201(2):207-13.
16. Ovsyannikova IG, Dhiman N, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, et al. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum Genet. 2010;127:207-21.
17. Dhiman N, Haralambieva IH, Kennedy RB, Vierkant RA, O'Byrne MM, Ovsyannikova IG, et al. SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine. Immunogenetics. 2010;62(4):197-210.
18. Kennedy RB, Ovsyannikova IG, Pankratz VS, Haralambieva IH, Vierkant RA, Jacobson RM, et al. Genome-wide genetic associations with IFNgamma response to smallpox vaccine. Hum Genet. 2012;131(9):1433-51.
19. Haralambieva IH, Ovsyannikova IG, Dhiman N, Kennedy RB, O'Byrne M, Pankrantz VS, et al. Common SNPs/haplotypes in IL18R1 and IL18 genes are associated with variations in humoral immunity to smallpox vaccination in Caucasians and African-Americans. J Infect Dis. 2011;204(3):433-41.
20. Ovsyannikova IG, Haralambieva IH, Kennedy RB, Pankratz VS, Vierkant RA, Jacobson RM, et al. Impact of cytokine and cytokine receptor gene polymorphisms on cellular immunity after smallpox vaccination. Gene. 2012;510:59-65.
21. Kennedy RB, Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Ryan MA, et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine. 2009;27(25-26):3319-23.
22. Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Human leukocyte antigen genotypes in the genetic control of adaptive immune responses to smallpox vaccine. J Infect Dis. 2011;203(11):1546-55.
23. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol. 2004;65:1506-15.
24. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J Infect Dis. 2005;191(4):515-9.
25. Ovsyannikova IG, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, Poland GA. The association of CD46, SLAM, and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses - a replication study and examination of novel polymorphisms. Hum Hered. 2011;72(3):206-23.
26. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Consistency of HLA associations between two independent measles vaccine cohorts: a replication study. Vaccine. 2012;30(12):2146-52.
27. Ovsyannikova IG, Ryan JE, Vierkant RA, O'Byrne MM, Jacobson RM, Poland GA. Influence of host genetic variation on rubella-specific T cell cytokine responses following rubella vaccination. Vaccine. 2009;27:3359-66.
28. Chen MH, Zhu Z, Zhang Y, Favors S, Xu WB, Featherstone DA, et al. An indirect immunocolorimetric assay to detect rubella virus infected cells. J Virol Methods. 2007;146(1-2):414-8.
29. Cleveland WS, Gross E, Shyu WM. Local regression models. In: Chambers JM, Hastie TJ, editors. Statistical models. Pacific Grove, CA: Wadsworth and Brooks/Cole; 1992.
30. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338-49.
31. Newport MJ, Goetghebuer T, Weiss HA, The MRCGTSG, Whittle H, Siegrist CA, et al. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 2004;5(2):122-9.
32. Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz SV. Twin studies of immunogenicity - determining the genetic contribution to vaccine failure. Vaccine. 2001;19:2434-9.
33. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther. 2007;82(6):653-64.
34. Haralambieva IH, Oberg AL, Ovsyannikova IG, Kennedy RB, Grill DE, Middha S, et al. Genome-wide characterization of transcriptional patterns in high and low antibody responders to rubella vaccination. PLoS One. 2013;8(5):e62149.
35. Pankratz VS, Vierkant RA, O'Byrne MM, Ovsyannikova IG, Poland GA. Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. BMC Immunol. 2010;11(1):48.
36. Ovsyannikova IG, Jacobson RM, Vierkant RA, O'Byrne MM, Poland GA. Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine. 2009;27(49):6926-31.
37. Skendzel LP. Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol. 1996;106(2):170-4.
38. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197(7):950-6.
39. O'Shea S, Best JM, Banatvala JE, Marshall WC, Dudgeon JA. Rubella vaccination: persistence of antibodies for up to 16 years. Br J Med. 1982;285(July):253-5.
40. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903-15.
41. LeBaron CW, Forghani B, Matter L, Reef SE, Beck C, Bi D, et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis. 2009;200(6):888-99.
42. Greenwood NP, Ovsyannikova IG, Vierkant RA, O'Byrne MM, Poland GA. A qualitative and quantitative comparison of two rubella virus-specific IgG antibody immunoassays. Viral Immunol. 2010;23(4):353-7.
43. Tosh PK, Kennedy RB, Vierkant RA, Jacobson RM, Poland GA. Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity. Viral Immunol. 2009;22(6):451-6.
44. Elser B, Lohoff M, Kock S, Giaisi M, Kirchhoff S, Krammer PH, et al. IFN-gamma represses IL-4 expression via IRF-1 and IRF-2. Immunity. 2002;17(6):703-12.
45. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 1987;236(4804):944-7.
46. Finkelman FD, Katona IM, Mosmann TR, Coffman RL. IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses. Journal of Immunology. 1988;140(4):1022-7.
47. Hegazy AN, Peine M, Helmstetter C, Panse I, Frohlich A, Bergthaler A, et al. Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions. Immunity. 2010;32(1):116-28.
48. Fletcher HA. Correlates of immune protection from tuberculosis. Curr Mol Med. 2007;7(3):319-25.
49. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol. 2005;174(1):449-55.
50. Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, Lang T, et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine. 2006;24(22):4709-15.
51. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun. 2006;74(10):5933-42.